COMPARATIVE EFFICACY OF INTRAARTICULAR THERAPY OF GONARTHROSIS WITH HYALURONIC ACID OF DIFFERENT MOLECULAR WEIGHT (A DOUBLE-BLIND RANDOMI7ED STUDY)

Objectives. To study the comparative efficacy and safety of intra-articular treatment of knee osteoarthritis (OA) with hyaluronic acid (HA) of different molecular weights (MW). Material and methods. Randomized double-blind controlled study included 50 patients with osteoarthritis of the knee stage II-III, weight-bearing pain more 40 mm on VAS and Lequesne index score > 4 and < 12. 25 patients received HA with MW 3500 kDa (Rusvisk group) and 25 patients were treated with HA with MW 1200-1400 kDa (Ostenil group) injected at 3-weekly intervals. During the 22-week observation period we assessed dynamics of pain on VAS (weightbearing pain, pain at rest), index WOMAC, and recorded the overall assessment of the effectiveness of therapy by patient and physician, OMERACT-OARSI criteria and the need for NSAIDs. Results. One week after the last injection, a significant decrease in weight-bearing pain (in the group Rusvisk by 69% in the group Ostenil 55%) and the total index WOMAC (group Rusvisk by 63% in the group Ostenil 60%), continuing until the end of observation. A significant decrease in pain at rest observed in the group Rusvisk at all visits and in the group Ostenil only at 6 and 10 weeks of therapy. The overall evaluation of effectiveness of therapy by patient and physician yielded the benefits observed in high molecular HA group. A high percentage of responses to therapy using OMERACT-OARSI criteria and reduced need for NSAIDs were observed in both groups. Tolerability was satisfactory and did not differ significantly between the groups. Most common adverse reactions were mild pain at the injection site. Conclusion. Intra-articular therapy with HA of different molecular weight Rusvisk and Ostenil resulted in pain reduction and improved joint function in patients with knee OA with satisfactory tolerability.

knee osteoarthritis, hyaluronic acid, intra-articular treatment, pain, tolerability

1. Dieppe P. Osteoarthritis. Acta Orthop Scand Suppl. 1998; 281: 2-5.

2. Peat G., McCarney R., Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001; 60: 91-7

3. WHO Library Cataloguing-in-Publication Data. - 2008.

4. Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011; 13(6): 513-20.

5. Галушко Е.А., Большакова Т.Ю., Виноградова И.Б., Иванова О.Н., Лесняк О.М. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования. Научно-практическая ревматология. 2009; № 1: С.1-17.

6. Conrozier T., Jerosch J., Beks P. Prospective, multicentre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009 Mar; 129(3): 417-23.

7. Swięchowicz S., Ostałowska A., Kasperczyk A., et al. Evaluation of hyaluronic acid intra-articular injections in the treatment of primary and secondary osteoarthritis of the knee. Pol Orthop Traumatol. 2012 Oct; 22; 77: 105-9.

8. Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62: 1145-1155.

9. Zhang W., Moskowitz R.W., Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008 Feb; 16(2): 137-62.

10. Hochberg M.C., Altman R.D., April K.T. American College of Rheumatology 2012. Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. April 2012; Vol. 64. No. 4: 465-474.

11. Bannuru R.R., Natov N.S., Obadan I.E., et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009 Dec; 15; 61(12): 1704-11.

12. Navarro-Sarabia F., Coronel P., Collantes E., et al. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011 Nov; 70(11): 1957-62.

13. Reichenbach S., Blank S., Rutjes A.W. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007 Dec; 15; 57(8): 1410-8.

14. Maheu E., Zaim M., Appelboom T. et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011 May-Jun; 29(3): 527-35.

15. Colen S., van den Bekerom M.P., Mulier M., et al. Hyaluronic Acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012 Aug 1; 26(4): 257-68.

16. Lee P.B., Kim Y.C., Lim Y.J. Comparison between High and Low molecular weight hyaluronates in knee osteoarthritis patient: open-label, randomized, multicentre clinical trial. The Journal of International Medical Research. 2006; 34: 77-87.

17. Berenbaum F., Grifka J., Cazzaniga S., et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. 2012 Sep; 71(9): 1454-60.

18. Altman R. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991; 27: 10-2.

19. Kellgren J.H., Lawrence J.S. Radiografhic assessment of osteoarthritis. Ann. Rheum. Dis. 1957; (16): 494-501.

20. Михайлова А.С., Теплякова О.В., Соколова Л.А. Влияние локальной терапии гонартроза препаратами гиалуроновой кислоты различной молекулярной массы на динамику альгофункциональных индексов. Фарматека. 2011; (19): 74-78.

21. Maheu E., Zaim M., Appelboom T. et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011 May-Jun; 29(3): 527-35.

22. Shen X., Gatti R. The safety and efficacy of intra-articular dual molecular weighted hyaluronic Acid in the treatment of knee osteoarthritis: the I.d.e.h.a. Study. Orthop Rev (Pavia). 2013 Dec 10; 5(4).

23. Pullman-Mooar S., Mooar P., Sieck M., et al. Clayburne G., Schumacher H.R. Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol. 2002 Dec; 29(12): 2611-4.

24. Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002; 32(1): 10-37.

25. Moskowitz R.W., Kelly M.A., Lewallen D.G. Understanding osteoarthritis of the knee-causes and effects. Am J Orthop (Belle Mead NJ). 2004 Feb; 33(2 Suppl): 5-9.

26. Vincent H.K., Percival S.S., Conrad B.P., et al. Hyaluronic Acid (HA) Viscosupplementation on Synovial Fluid Inflammation in Knee Osteoarthritis: A Pilot Study. Open Orthop J. 2013 Sep 20; 7: 378-84.